Factors associated with APOs versus delivery in patients with RA
| Variables | Univariable analysis (n=5728) | Multivariable analysis (n=5672) | ||
| OR (95% CI) | P value | Adjusted OR (95% CI) | P value | |
| Age group, years (ref: 20–29) | ||||
| 30–39 | 1.34 (1.08 to 1.65) | 0.008 | 1.33 (1.07 to 1.66) | 0.010 |
| 40–49 | 5.46 (4.27 to 6.97) | <0.001 | 5.35 (4.16 to 6.89) | <0.001 |
| Type of insurance (ref: NHI) | 2.13 (1.18 to 3.84) | 0.012 | 1.39 (0.72 to 2.69) | 0.328 |
| Type of institution (ref: tertiary referral hospital) | ||||
| General hospital | 1.05 (0.88 to 1.26) | 0.567 | 0.93 (0.77 to 1.13) | 0.474 |
| Community hospital/clinic | 3.26 (2.77 to 3.83) | <0.001 | 1.33 (1.13 to 1.56) | <0.001 |
| Income group (ref: first quartile) (n=5672) | ||||
| Second quartile | 0.72 (0.59 to 0.89) | 0.002 | 0.78 (0.63 to 0.97) | 0.026 |
| Third quartile | 0.80 (0.67 to 0.97) | 0.020 | 0.87 (0.71 to 1.06) | 0.152 |
| Fourth quartile | 0.88 (0.72 to 1.08) | 0.210 | 0.84 (0.68 to 1.04) | 0.116 |
| Seropositivity (ref: seronegative) | 1.02 (0.89 to 1.16) | 0.797 | 0.95 (0.81 to 1.11) | 0.49 |
| CCI score | 1.07 (1.00 to 1.14) | 0.070 | 1.04 (0.97 to 1.12) | 0.246 |
| Any hospital visit for RA during early pregnancy* | 0.98 (0.85 to 1.14) | 0.826 | 0.95 (0.78 to 1.17) | 0.638 |
| Conventional synthetic DMARD† | ||||
| Methotrexate use (ref: not use) | 2.28 (0.72 to 2.95) | <0.001 | 2.14 (1.57 to 2.92) | <0.001 |
| Leflunomide use (ref: not use) | 4.59 (2.58 to 8.17) | <0.001 | 2.68 (1.39 to 5.15) | 0.003 |
| Hydroxychloroquine use (ref: not use) | 1.10 (0.93 to 1.30) | 0.286 | 1.12 (0.91 to 1.39) | 0.292 |
| Sulfasalazine use (ref: not use) | 0.89 (0.69 to 1.15) | 0.368 | 0.86 (0.64 to 1.15) | 0.303 |
| Tacrolimus use (ref: not use) | 1.30 (0.81 to 2.06) | 0.277 | 0.95 (0.57 to 1.59) | 0.856 |
| NSAIDs use† (ref: not use) | 1.20 (1.06 to 1.37) | 0.006 | 1.15 (0.95 to 1.40) | 0.140 |
| Oral GC use† (ref: not use) | 1.00 (0.88 to 1.15) | 0.972 | 0.95 (0.81 to 1.11) | 0.507 |
| Targeted therapy† (ref: not use) | 1.30 (0.91 to 1.87) | 0.147 | 1.21 (0.81 to 1.81) | 0.355 |
| Multiple pregnancies (ref: single pregnancy) | 1.15 (1.01 to 1.31) | 0.036 | 1.10 (0.96 to 1.26) | 0.179 |
*The first 12 weeks from conception.
†Medication use in the 3 months prior to conception.
APO, adverse pregnancy outcome; CCI, Charlson Comorbidity Index; DMARD, disease-modifying antirheumatic drug; GC, glucocorticoid; NHI, National Health Insurance; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis.